Neurotrope Inc. (NTRP) Starts Presentation at 9th Annual LD Micro Invitational
Neurotrope (NASDAQ: NTRP) is at the forefront of developing a new approach to combating Alzheimer’s disease (AD) and other neurodegenerative diseases. The company’s world-class science offers the potential to realize a paradigm shift to overcome one of today’s most challenging clinical problems — finding a way to slow or even prevent the progression of AD. In addition to the company’s phase 2 trial of Bryostatin-1 in advanced AD, Neurotrope has also conducted preclinical studies of Bryostatin-1 as a potential treatment for various rare diseases and brain injury. The U.S. FDA has granted Orphan Drug Designation to Neurotrope for Bryostatin-1 as…